Replies to post #115535 on Biotech Values

[jq1234]

The Yahoo crowd seems to think that a financing will be forthcoming soon. Do you see a risk of financing this year?

Yahoo crowd can always be divided into two camps: one camp is the stock is going down to zero, the other camp is the stock is going to a zillion. The few reasonable ones usually get drown out during binary event.

I don't know if PLX is going to do financing or not this year. They might, they might not. They could wait for FDA or EMA decision to get milestone payment from PFE. Or they could be more conservative, get the money now.

As someone who is just watching from the sideline, I think I'd be inclined to wait for this before considering a position.

It is worth of watching. I remember last year the stock got into $5 range after FDA designated 10-month review, and overall stock market was crashing. Only when in rear view mirror one would know that was the best time to get in. It is always difficult to judge at the moment.

[jq1234]

One of the biq questions that came up during Q&A related to hypersensitivity and management claimed that they've seen a 7% hypersensitivity rate in their trials of Uplyso, which is similar to Cerezyme. Also, the magnitude of the hypersensitivity is apparently similar as well.

This is one reason I like PLX management. Numerically, Uplyso produced better number in quite a few parameters in its trial than from Cerezyme trial both pre and post approval trial. However, PLX never claimed Uplyso is better than Cerezyme or Vpriv because it has not done superiority comparison trial. They always say they are similar. If other companies have a drug like this, you would hear so much about their so called "advantage" over other drugs conference after conference.